References
  1. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017-1032.
  2. Goldenberg NA, Sochet A, Albisetti M, Biss T, Bonduel M, Jaffray J, MacLaren G, Monagle P, O’Brien S, Raffini L, et al.; Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee of the ISTH SSC. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020;18:3099-3105.
  3. Loi M, Branchford B, Kim J, Self C, Nuss R. COVID-19 anticoagulation recommendations in children. Pediatr Blood Cancer. 2020;67:e28485.
  4. Mathuria JP, Yadav R, Rajkumar. Laboratory diagnosis of SARS-CoV-2 - A review of current methods. J Infect Public Health. 2020;13(7):901-905.
  5. Kotula JJ, Balakumar N, Khan D, Patel B. Bilateral pulmonary emboli in a teenager with positive SARS-CoV-2 antibody. Pediatr Pulmonol. 2021;56:271-273.
  6. Martinelli I, Ferrazzi E, Ciavarella A, Erra R, Iurlaro E, Ossola M, Lombardi A, Blasi F, Mosca F, Peyvandi F. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res. 2020;191:36-37
  7. Hussain Z, Wangmo R, Gonbo S. Deep Vein Thrombosis After Trivial Blunt Trauma at High Altitude in a SARS-CoV-2 Positive Child: Complication of the Hypercoagulable State. Indian Pediatr. 2020;57:1182-1183
  8. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.
  9. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020;48:1358-1364..
  10. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995-2002.
  11. Thachil J, Srivastava A. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism? Semin Thromb Hemost. 2020;46:777-780.
  12. Wit JM, Hero M, Nunez SB. Aromatase inhibitors in pediatrics. Nat Rev Endocrinol. 2011;8:135-47.
  13. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T; ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802-10.
  14. Diaz-Thomas A, Shulman D. Use of aromatase inhibitors in children and adolescents: what’s new? Curr Opin Pediatr. 2010;22:501-7.
  15. Zhou B, She J, Wang Y, Ma X. Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report. J Thromb Thrombolysis. 2020;50:229-232.
  16. Franch-Llasat D, Mayor-Vázquez E, Pedregosa-Díaz J, Herrero-Redondo M, Ortin-Font X, Roche-Campo F. e-Thrombosis in the COVID-19 era: collateral effects of confinement. Med Intensiva (Engl Ed). 2021;45:122-124.
  17. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020 Oct;194:101-115.
  18. Colling ME, Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vasc Med. 2020;25:471-478
  19. Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response. Clin Appl Thromb Hemost. 2020;26:1076029620943293.
  20. Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24:353
  21. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-1418.
  22. Müller MM, Griesmacher A. Markers of endothelial dysfunction. Clin Chem Lab Med. 2000;38:77-85.
  23. Rauch A, Labreuche J, Lassalle F, Goutay J, Caplan M, Charbonnier L, Rohn A, Jeanpierre E, Dupont A, Duhamel A et al. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19. J Thromb Haemost. 2020;18:2942-2953
  24. Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern Emerg Med. 2021;16:309-312.
  25. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24:360.
  26. Gazzaruso C, Paolozzi E, Valenti C, Brocchetta M, Naldani D, Grignani C, Salvucci F, Marino F, Coppola A, Gallotti P. Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity. Nutr Metab Cardiovasc Dis. 2020;30:1914-1919.
  27. Maldonado E, Tao D, Mackey K. Antithrombotic Therapies in COVID-19 Disease: a Systematic Review. J Gen Intern Med. 2020;35:2698-2706.
  28. Lippi G, Henry BM, Sanchis-Gomar F. Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness. Semin Thromb Hemost. 2021;47:460-462.